• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征的发病率和患病率:杜塞尔多夫 MDS 登记处的数据。

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.

机构信息

Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.

出版信息

Leuk Res. 2011 Dec;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001. Epub 2011 Jun 25.

DOI:10.1016/j.leukres.2011.06.001
PMID:21708407
Abstract

Population-based data on patients with MDS are scarce. Here we report the incidence and prevalence of MDS based on data from the Düsseldorf MDS Registry. Cases in the city of Düsseldorf in the study period were identified from the MDS Registry. We calculated crude, calendar-year, age- and sex-specific and European Standard Population age-standardized incidence rates as well as point prevalences per 100,000 The crude incidence rate was 4.15/100,000/year and the point prevalence per 100,000 persons of 7. We found that the incidence and prevalence of MDS was higher in men than women and increased sharply with increasing age.

摘要

人群中 MDS 患者的数据较为匮乏。在此,我们报告了基于杜塞尔多夫 MDS 注册中心数据的 MDS 发病率和患病率。研究期间,从 MDS 注册中心确定了杜塞尔多夫市的病例。我们计算了粗发病率、日历年度发病率、年龄和性别特异性发病率以及欧洲标准人口年龄标准化发病率,以及每 10 万人的时点患病率。粗发病率为 4.15/100,000/年,每 10 万人的时点患病率为 7。我们发现,MDS 的发病率和患病率男性高于女性,且随年龄增长急剧上升。

相似文献

1
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.骨髓增生异常综合征的发病率和患病率:杜塞尔多夫 MDS 登记处的数据。
Leuk Res. 2011 Dec;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001. Epub 2011 Jun 25.
2
No increase in age-specific incidence of myelodysplastic syndromes.骨髓增生异常综合征的年龄特异性发病率无增加。
Haematologica. 2004 Aug;89(8):905-10.
3
Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006.2005-2006 年,华盛顿州西部地区非营利性医疗机构中骨髓增生异常综合征的发病率。
Am J Hematol. 2010 Oct;85(10):765-70. doi: 10.1002/ajh.21828.
4
[Myelodysplastic syndromes. The epidemiological and etiological aspects].[骨髓增生异常综合征。流行病学和病因学方面]
Dtsch Med Wochenschr. 1992 Aug 14;117(33):1223-31. doi: 10.1055/s-2008-1062434.
5
[Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias].[骨髓增生异常综合征的演变性流行病学特征(1959 - 1993年)。与急性髓系白血病和再生障碍性全血细胞减少症的比较研究]
Sangre (Barc). 1994 Dec;39(6):441-8.
6
The long term risk of myelodysplastic syndromes among anemia patients: a population-based study.贫血患者骨髓增生异常综合征的长期风险:一项基于人群的研究。
Leuk Res. 2012 Mar;36(3):327-30. doi: 10.1016/j.leukres.2011.11.008. Epub 2011 Dec 3.
7
Myelodysplastic syndromes: incidence and survival in the United States.骨髓增生异常综合征:美国的发病率与生存率
Cancer. 2007 Apr 15;109(8):1536-42. doi: 10.1002/cncr.22570.
8
Myelodysplastic syndrome in New Zealand and Australia.新西兰和澳大利亚的骨髓增生异常综合征。
Intern Med J. 2012 Nov;42(11):1235-42. doi: 10.1111/j.1445-5994.2011.02619.x.
9
Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania.罗马尼亚某单一医院中心骨髓增生异常综合征患者登记处的流行病学数据。
Leuk Res. 2009 Nov;33(11):1556-61. doi: 10.1016/j.leukres.2009.03.034. Epub 2009 May 2.
10
Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.癌症登记处低估骨髓增生异常综合征发病率:基于人群数据链接研究的结果。
Cancer. 2014 Jun 1;120(11):1686-94. doi: 10.1002/cncr.28641. Epub 2014 Mar 18.

引用本文的文献

1
Inflammatory signaling in the pathogenesis of acute myeloid leukemia.急性髓系白血病发病机制中的炎症信号传导
Hemasphere. 2025 Aug 13;9(8):e70188. doi: 10.1002/hem3.70188. eCollection 2025 Aug.
2
Perceptions and Needs of Stakeholders Regarding MyPal Project's Electronic Patient-Reported Outcome App: Cross-Sectional Qualitative Focus Group Study.利益相关者对MyPal项目电子患者报告结局应用程序的认知与需求:横断面定性焦点小组研究
JMIR Cancer. 2025 Aug 13;11:e57388. doi: 10.2196/57388.
3
Myelodysplastic syndromes: A primary care perspective.
骨髓增生异常综合征:基层医疗视角
S Afr Fam Pract (2004). 2025 Jul 14;67(1):e1-e6. doi: 10.4102/safp.v67i1.6118.
4
The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms.BCL-2表达在骨髓增生异常肿瘤患者中的作用
Curr Issues Mol Biol. 2025 May 10;47(5):346. doi: 10.3390/cimb47050346.
5
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.非治愈性疗法及其对骨髓增生异常综合征患者预后的影响——一项回顾性配对分析
Ann Hematol. 2025 Jun 27. doi: 10.1007/s00277-025-06485-w.
6
Clinical management of CMML-State of the art.慢性粒单核细胞白血病的临床管理——最新进展
Br J Haematol. 2025 Aug;207(2):350-364. doi: 10.1111/bjh.20213. Epub 2025 Jun 24.
7
Accelerated senescence of bone marrow erythrocyte precursors in myelodysplastic syndrome.骨髓增生异常综合征中骨髓红细胞前体细胞的加速衰老。
Ann Med. 2025 Dec;57(1):2494676. doi: 10.1080/07853890.2025.2494676. Epub 2025 Apr 25.
8
Burden of myelodysplastic syndromes: a systematic literature review of economic burden.骨髓增生异常综合征的负担:经济负担的系统文献综述
Eur J Health Econ. 2025 Apr 23. doi: 10.1007/s10198-025-01779-2.
9
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes.基于人群的研究在增进我们对骨髓增生异常综合征认识方面的作用。
Curr Hematol Malig Rep. 2025 Jan 17;20(1):6. doi: 10.1007/s11899-025-00750-5.
10
MDS patient registries - achievements and challenges.骨髓增生异常综合征患者登记处——成就与挑战。
Ann Hematol. 2024 Dec;103(12):4913-4930. doi: 10.1007/s00277-024-05925-3. Epub 2024 Aug 23.